Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML

Blood

Volumn 102, Issue 9, 2003, Pages 3097-3099

  Estey, Elihu H ^a   Thall, Peter F ^b   Wang, Xuemei ^b   Verstovsek, Srdan ^b   Cortes, Jorge ^b   Kantarjian, Hagop M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BAYES THEOREM; BLAST CELL; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MD ANDERSON CRITERIA; MULTIVARIATE ANALYSIS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; RELAPSE; REMISSION; RISK ASSESSMENT; SCORING SYSTEM; STANDARD; STATISTICAL SIGNIFICANCE;

EID: 0142214653     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1309     Document Type: Article

References (11)

1. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-Sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8: 813-819.
2. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
3. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;60:163-170.
4. Gelman A, Carlin JB, Stem HS, Rubin DB. Bayesian Data Analysis. New York: Chapman Hall; 1995.
5. Estey E, Thall P, Giles F, et al. Gemtuzumab ozogamycin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin + continuous-infusion high-dose cytosine arabinoside. Blood. 2002;99:4343-4349.
6. Spiegelhalter D, Thomas A, Best N, Gilks W. Bayesian Inference Using Gibbs Sampling Manual (BUGS 0.5). Cambridge, United Kingdom: MRC Biostatistics Unit; 1995.
7. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
8. Therneau TM, Grambsch P. Modeling Survival Data. New York, NY: Springer; 2000.
9. Venables WN, Ripley BD. Modern Applied Statistics with Splus, 3rd ed. New York: Springer; 1999.
10. Estey E, Thall P, Cortes J, et al. Comparison of idarubicin + ara-C, fludarabine + ara-C, and topotecan + ara-C-based regimens in treatment of newly-diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575-3583.
11. Estey E. Growth factors in acute myeloid leukemia. Best Pract Res Clin Haematol. 2001;14:175-187.